GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (XPAR:VLA) » Definitions » Beta

Valneva SE (XPAR:VLA) Beta : 1.06 (As of May. 17, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Valneva SE Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-17), Valneva SE's Beta is 1.06.


Valneva SE Beta Historical Data

The historical data trend for Valneva SE's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Beta Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.43 0.11 0.75 1.06

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.64 0.86 1.06 1.15

Competitive Comparison of Valneva SE's Beta

For the Biotechnology subindustry, Valneva SE's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Beta distribution charts can be found below:

* The bar in red indicates where Valneva SE's Beta falls into.



Valneva SE Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Valneva SE  (XPAR:VLA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Valneva SE Beta Related Terms

Thank you for viewing the detailed overview of Valneva SE's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (XPAR:VLA) Business Description

Traded in Other Exchanges
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (XPAR:VLA) Headlines

No Headlines